Fosrenol FDA Approval History
FDA Approved: Yes (First approved October 26, 2004)
Brand name: Fosrenol
Generic name: lanthanum carbonate
Dosage form: Chewable Tablets
Company: Shire Pharmaceuticals Group plc
Treatment for: Hyperphosphatemia of Renal Failure
Fosrenol is a phosphate binder used to reduce high phosphorus levels in end-stage renal disease (ESRD) patients.
Development Timeline for Fosrenol
|Oct 26, 2004||ApprovalFosrenol Shire Pharmaceuticals Group plc - Treatment for Hyperphosphataemia in ESRD Patients|
|Jul 20, 2004||Fosrenol: FDA Action Date Extended, US Launch Target Unaffected|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.